Iressa Therapy Should Not Be Limited To Patients With EGFR Mutation, Researchers Say
This article was originally published in The Pink Sheet Daily
Executive Summary
Data published in New England Journal of Medicine suggest that patients with mutations in the EGFR gene are more likely to experience clinical responsiveness to Iressa therapy. However, patients who are mutation negative may still benefit, researchers contend.